SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Ewenstein B. M.)
 

Search: WFRF:(Ewenstein B. M.) > Factor VIII require...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003678naa a2200445 4500
001oai:DiVA.org:uu-123015
003SwePub
008100422s2010 | |||||||||||000 ||eng|
024a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-1230152 URI
024a https://doi.org/10.1111/j.1538-7836.2009.03703.x2 DOI
040 a (SwePub)uu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
100a Collins, P. W.4 aut
2451 0a Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A :b influences of variance in pharmacokinetics and treatment regimens
264 1b International Society on Thrombosis and Haemostasis,c 2010
338 a print2 rdacarrier
520 a BACKGROUND: Prophylactic factor (F)VIII has been shown to reduce bleeds and arthropathy in patients with severe hemophilia A. OBJECTIVES: Assuming that the trough FVIII level is an important determinant of the efficacy of prophylaxis, this paper addresses the effect of the inter-patient variability in pharmacokinetics and different dosing regimens on trough levels. METHODS: Simulations used FVIII half-lives and in vivo recoveries (IVR), observed during clinical trials with Advate [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method], and commonly used prophylactic regimens to calculate their effect on FVIII levels during prophylaxis. RESULTS AND CONCLUSIONS: Half-life and dose frequency had a larger effect on trough FVIII and time per week with FVIII<1 IU dL(-1) than IVR and infused dose per kg. The combined effect of these parameters resulted in substantial inter-patient variability in the amount of FVIII required to sustain a desired trough level. Prophylactic regimens based on Monday, Wednesday, Friday dosing were less cost effective in maintaining a desired trough level throughout the week. Dose escalation on Friday to cover the weekend would require potentially harmful doses of FVIII in many patients, especially in young children where more than 50% would require a Friday dose of over 100 IU kg(-1) and some would require more than 400 IU kg(-1). Knowledge of individual patients' half-lives and alteration of frequency of infusions may allow the more cost-effective use of FVIII and potentially expand access to prophylaxis to a greater number of patients, especially in regions where healthcare resources are scarce.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Farmaceutiska vetenskaper0 (SwePub)301012 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Pharmaceutical Sciences0 (SwePub)301012 hsv//eng
653 a PHARMACY
653 a FARMACI
653 a MEDICINE
653 a MEDICIN
700a Björkman, Svenu Uppsala universitet,Institutionen för farmaceutisk biovetenskap,PKPD4 aut0 (Swepub:uu)svbjo103
700a Fischer, K.4 aut
700a Blanchette, V.4 aut
700a Oh, M.4 aut
700a Schroth, P.4 aut
700a Fritsch, S.4 aut
700a Casey, K.4 aut
700a Spotts, G.4 aut
700a Ewenstein, B. M.4 aut
710a Uppsala universitetb Institutionen för farmaceutisk biovetenskap4 org
773t Journal of Thrombosis and Haemostasisd : International Society on Thrombosis and Haemostasisg 8:2, s. 269-275q 8:2<269-275x 1538-7933x 1538-7836
856u https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1538-7836.2009.03703.x
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-123015
8564 8u https://doi.org/10.1111/j.1538-7836.2009.03703.x

Find in a library

To the university's database

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view